← Back to Home

Petosemtamab Plus Immunotherapy Meets Phase 3 Endpoints, Reduces Risk of Death by 50% in Head and Neck Cancer

In patients with PD-L1-positive recurrent or metastatic head and neck cancer, a bispecific antibody combined with pembrolizumab improved both overall survival and tumor response. The first interim analysis provides new evidence, but full data are still needed to determine how much longer patients live and the extent of the treatment burden.

By SURL BioNews

For patients with recurrent or metastatic head and neck cancer, whether treatment can extend life is a more critical question than whether it shrinks tumors. Genmab announced on October 28 that the investigational drug petosemtamab combined with the immunotherapy pembrolizumab met both primary endpoints of overall survival and objective response rate at the first interim analysis of the Phase 3 LiGeR-HN1 trial, providing new clinical evidence for this chemotherapy-free combination.

The study compared the combination with pembrolizumab alone as first-line treatment for PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. Following assessment by an independent data monitoring committee, the hazard ratio for death in the combination group was 0.50, with a 95% confidence interval of 0.37 to 0.67, reaching statistical significance. A 50% reduction in the risk of death describes the relative difference in the risk of death between the two groups during follow-up. It cannot be directly interpreted as a doubling of lifespan or a 50-percentage-point increase in the survival rate at a particular time.

Tumor response also improved: the odds ratio for objective response was 3.17, reflecting higher odds of meeting the predefined criteria for tumor shrinkage in the combination group, rather than a tripling of the response rate. The company said benefits were observed across patients with different human papillomavirus (HPV) statuses. However, the announcement has not yet provided actual response rates for each group, median overall survival, or detailed subgroup results, making it difficult to characterize the absolute benefit patients may receive.

According to additional information from OncLive, LiGeR-HN1 is a global, multicenter, open-label trial in which patients were randomized one to one. Eligible patients were required to have a PD-L1 combined positive score (CPS) of at least 1, no prior systemic treatment in the incurable recurrent or metastatic setting, and an ECOG performance status of 0 to 1, indicating relatively good ability to carry out daily activities. These criteria define the population to which the current evidence applies; the findings cannot be directly generalized to all patients with head and neck cancer.

Petosemtamab is a bispecific antibody that recognizes both EGFR and LGR5. It is designed to block EGFR signaling that promotes tumor growth while also inducing EGFR internalization and degradation in cells expressing both receptors. Combining it with the immune checkpoint inhibitor pembrolizumab is an attempt to combat tumors through different pathways working together. The survival improvement demonstrated in this randomized trial adds support for this strategy.

On safety, Genmab said no new safety signals were identified and that the overall profile was consistent with the known safety profiles of the two drugs. However, the announcement has not yet listed detailed rates of serious adverse events, treatment discontinuation, or treatment-related deaths, so a full comparison of the treatment burden associated with adding another drug is not yet possible. The absence of new safety signals also does not mean the combination carries no additional risks.

Genmab plans to discuss the results with regulatory authorities in various countries and submit the full data for presentation at a future medical meeting. Petosemtamab remains investigational. The forthcoming full data, particularly survival curves, duration of response, and adverse events, will help determine whether these interim findings can translate into a new first-line treatment option.

References

  1. Genmab via SEC
  2. OncLive